

Jan '24:

Cancer Site	24/24 (93%)	28 Day FDS (78%)	31 Day Standard (96%)	62 Day (70%)
Breast	56.6% (118/272)	88.2% (31/262)	88.9% (4/36)	75.7% (45/185)
Colorectal	64.3% (74/207)	32.1% (23/140)	100.0% (0/11)	43.6% (65/111)
Gynaecology	30.8% (15/65)	95.4% (11/17)	63.7% (37/102)	71.1% (17/77)
Haematology	0.0% (0/13)	59.1% (4.5/11)	70.0% (3/10)	20.0% (8/10)
Head and Neck	100.0% (0/0)	72.1% (20/105)	100.0% (0/0)	100.0% (0/0)
Skin	77.2% (13/53)	61.5% (10/26)	21.0% (2/9)	91.0% (10/11)
Upper GI	100.0% (0/16)	75.9% (3.5/14.5)	71.2% (21/73)	74.7%
Urology	100.0% (1/10)	58.3% (11/17.5)	97.2% (2/10)	43.5%
Total	72.9% (34/125.5)	71.3% (288/1002)	69.9% (348/1156)	91.8% (15/184)

Feb '24:

Cancer Site	24/24 (93%)	28 Day FDS (78%)	31 Day Standard (96%)	62 Day (70%)
Breast	93.9% (2/33)	80.0% (3/15)	65.4% (101/292)	94.7% (16/17)
Colorectal	90.9% (1/11)	29.4% (6/8.5)	79.6% (32/157)	37.1% (15/40)
Gynaecology	100.0% (0/3)	71.4% (1/3.5)	95.3% (4/85)	72.2% (30/41)
Haematology	100.0% (0/24)	60.9% (4.5/11.5)	100.0% (0/6)	25.0% (6/8)
Head and Neck	60.0% (2/5)	46.2% (3.5/6.5)	83.6% (18/110)	76.1% (33/138)
Skin	100.0% (0/12)	85.0% (11/14)	100.0% (0/51)	91.1% (14/15)
Upper GI	1.5% (1/28/130)	68.2% (12/132)	82.0% (9/50)	93.6% (15/23.5)
Urology	70.4% (10.5/35.5)	99.1% (1/110)	55.3% (51/114)	97.1% (1/34)
Total	72.9% (34/125.5)	71.3% (288/1002)	69.9% (348/1156)	91.8% (15/184)

Mar '24:

Cancer Site	24/24 (93%)	28 Day FDS (78%)	31 Day Standard (96%)	62 Day (70%)
Breast	93.9% (2/33)	80.0% (3/15)	65.4% (101/292)	94.7% (16/17)
Colorectal	90.9% (1/11)	29.4% (6/8.5)	79.6% (32/157)	37.1% (15/40)
Gynaecology	100.0% (0/3)	71.4% (1/3.5)	95.3% (4/85)	72.2% (30/41)
Haematology	100.0% (0/24)	60.9% (4.5/11.5)	100.0% (0/6)	25.0% (6/8)
Head and Neck	60.0% (2/5)	46.2% (3.5/6.5)	83.6% (18/110)	76.1% (33/138)
Skin	100.0% (0/12)	85.0% (11/14)	100.0% (0/51)	91.1% (14/15)
Upper GI	1.5% (1/28/130)	68.2% (12/132)	82.0% (9/50)	93.6% (15/23.5)
Urology	70.4% (10.5/35.5)	99.1% (1/110)	55.3% (51/114)	97.1% (1/34)
Total	72.9% (34/125.5)	71.3% (288/1002)	69.9% (348/1156)	91.8% (15/184)